Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment
Cardiovascular diseases remain the primary cause of death in developed countries, including Poland, despite the progress in their treatment and a noticeable decrease in their prevalence. For this reason, the search for biomarkers for early disease risk assessment in primary as well as secondary pr...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Communications Sp. z o.o.
2018-03-01
|
| Series: | Pediatria i Medycyna Rodzinna |
| Subjects: | |
| Online Access: | http://www.pimr.pl/index.php/issues/2018-vol-14-no-1/growth-differentiation-factor-15-gdf-15-for-cardiovascular-risk-assessment?aid=1157 |
| _version_ | 1811302921087746048 |
|---|---|
| author | Wiesław Piechota Paweł Krzesiński |
| author_facet | Wiesław Piechota Paweł Krzesiński |
| author_sort | Wiesław Piechota |
| collection | DOAJ |
| description | Cardiovascular diseases remain the primary cause of death in developed countries, including Poland, despite the progress
in their treatment and a noticeable decrease in their prevalence. For this reason, the search for biomarkers for early disease
risk assessment in primary as well as secondary prevention is the main task. Growth differentiation factor-15 (GDF-15) is becoming
a leader among the new protein markers with a high predictive potential for cardiovascular diseases and their complications.
An elevated GDF-15 blood level is associated with an increased risk of many cardiovascular diseases, their subclinical
presence and their complications, including death. The predictive strength of GDF-15 is independent of and additive to other
risk factors. GDF-15 can be used as part of a multimarker strategy to improve risk stratification, although it can also be used
alone for death risk assessment. GDF-15 is not heart-specific: in some cardiovascular diseases its expression can be increased
in other tissues as well. Elevated GDF-15 blood levels are found in cancer. They are also observed in renal impairment. Due to
the strong relationship between GDF-15 and general mortality it is sometimes called “the marker of death.” Its increase often
precedes serious clinical events by many months or even years. This provides opportunities for more intensive prevention,
both primary and secondary. |
| first_indexed | 2024-04-13T07:37:57Z |
| format | Article |
| id | doaj.art-71acf9c628884e068bdc76aa1ce253ce |
| institution | Directory Open Access Journal |
| issn | 1734-1531 2451-0742 |
| language | English |
| last_indexed | 2024-04-13T07:37:57Z |
| publishDate | 2018-03-01 |
| publisher | Medical Communications Sp. z o.o. |
| record_format | Article |
| series | Pediatria i Medycyna Rodzinna |
| spelling | doaj.art-71acf9c628884e068bdc76aa1ce253ce2022-12-22T02:56:01ZengMedical Communications Sp. z o.o.Pediatria i Medycyna Rodzinna1734-15312451-07422018-03-0114191910.15557/PiMR.2018.0001Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessmentWiesław Piechota0Paweł Krzesiński1Department of Laboratory Medicine, Military Institute of Medicine, Warsaw, PolandDepartment of Cardiology and Internal Medicine, Military Institute of Medicine, Warsaw, PolandCardiovascular diseases remain the primary cause of death in developed countries, including Poland, despite the progress in their treatment and a noticeable decrease in their prevalence. For this reason, the search for biomarkers for early disease risk assessment in primary as well as secondary prevention is the main task. Growth differentiation factor-15 (GDF-15) is becoming a leader among the new protein markers with a high predictive potential for cardiovascular diseases and their complications. An elevated GDF-15 blood level is associated with an increased risk of many cardiovascular diseases, their subclinical presence and their complications, including death. The predictive strength of GDF-15 is independent of and additive to other risk factors. GDF-15 can be used as part of a multimarker strategy to improve risk stratification, although it can also be used alone for death risk assessment. GDF-15 is not heart-specific: in some cardiovascular diseases its expression can be increased in other tissues as well. Elevated GDF-15 blood levels are found in cancer. They are also observed in renal impairment. Due to the strong relationship between GDF-15 and general mortality it is sometimes called “the marker of death.” Its increase often precedes serious clinical events by many months or even years. This provides opportunities for more intensive prevention, both primary and secondary.http://www.pimr.pl/index.php/issues/2018-vol-14-no-1/growth-differentiation-factor-15-gdf-15-for-cardiovascular-risk-assessment?aid=1157growth differentiation factor-15biomarkercardiovascular risk |
| spellingShingle | Wiesław Piechota Paweł Krzesiński Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment Pediatria i Medycyna Rodzinna growth differentiation factor-15 biomarker cardiovascular risk |
| title | Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment |
| title_full | Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment |
| title_fullStr | Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment |
| title_full_unstemmed | Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment |
| title_short | Growth differentiation factor-15 (GDF-15) for cardiovascular risk assessment |
| title_sort | growth differentiation factor 15 gdf 15 for cardiovascular risk assessment |
| topic | growth differentiation factor-15 biomarker cardiovascular risk |
| url | http://www.pimr.pl/index.php/issues/2018-vol-14-no-1/growth-differentiation-factor-15-gdf-15-for-cardiovascular-risk-assessment?aid=1157 |
| work_keys_str_mv | AT wiesławpiechota growthdifferentiationfactor15gdf15forcardiovascularriskassessment AT pawełkrzesinski growthdifferentiationfactor15gdf15forcardiovascularriskassessment |